Vimarsana
Biggest News Aggregation in the World

Page 10 - Depression Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Depression Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Depression Scale Today - Breaking & Trending Today

Study finds men's antidepressant use did not - Vimarsana News

Study finds men's antidepressant use did not

<p>.In vitro fertilization (IVF) is a time-intensive and often stress-inducing fertility procedure. Yet how does that stress impact its success? Investigators at <a href="https://www.brighamandwomens.org/">Brigham and Women&rsquo;s Hospital</a>, a founding member of the <a href="https://www.massgeneralbrigham.org/">Mass General Brigham</a> healthcare system, assessed the effects of anxiety and depression in men on fertility and IVF outcomes</p>

Low-Dose Amitriptyline Offers Viable Second-Line Treatment for IBS - Vimarsana News

Low-Dose Amitriptyline Offers Viable Second-Line Treatment for IBS

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

GLP-1 Receptor Agonists Show Promise in Reducing Depressive Symptoms - Vimarsana News

GLP-1 Receptor Agonists Show Promise in Reducing Depressive Symptoms

Meta-analysis findings show that GLP-1 receptor agonists significantly reduced depressive symptoms for individuals with type 2 diabetes.

GLP-1 Receptor Agonists Show Promise in Reducing Depressive Symptoms - Vimarsana News

GLP-1 Receptor Agonists Show Promise in Reducing Depressive Symptoms

Meta-analysis findings show that GLP-1 receptor agonists significantly reduced depressive symptoms for individuals with type 2 diabetes.

GLP-1 Receptor Agonists Show Promise in Reducing Depressive Symptoms - Vimarsana News

GLP-1 Receptor Agonists Show Promise in Reducing Depressive Symptoms

Meta-analysis findings show that GLP-1 receptor agonists significantly reduced depressive symptoms for individuals with type 2 diabetes.